Autoren

David Mulder

Counsel

Read More

Christian Dekoninck

Partner

Read More

Adrian Toutoungi

Partner

Read More

Dr. Anja Lunze, LL.M.

Partnerin

Read More

Dr. Angela Knierim

Salary Partnerin

Read More
Autoren

David Mulder

Counsel

Read More

Christian Dekoninck

Partner

Read More

Adrian Toutoungi

Partner

Read More

Dr. Anja Lunze, LL.M.

Partnerin

Read More

Dr. Angela Knierim

Salary Partnerin

Read More

23. November 2020

Pharmaceutical patent law – 2 von 2 Insights

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

  • Quick read

Which extraordinary regulations have been put in place for speeding up clinical trials in emergency situations like the current coronavirus pandemic? And how is early access to new medicines warranted under such circumstance?

The second part of the two-part series ‘Pharmaceutical Patent Law in Times of Crisis: A Comparative Study’, written for the European Intellectual Property Review by our international team, addresses these questions and more on both a broad, European level and from the perspective of six national jurisdictions.
 

Read the article here

In dieser Serie

Patente und Innovationen

Pharmaceutical patent law in times of crisis: A comparative study – Part 1

9. November 2020

von mehreren Autoren

Patente und Innovationen

Pharmaceutical patent law in times of crisis: A comparative study – Part 2

23. November 2020

von mehreren Autoren

Call To Action Arrow Image

Newsletter-Anmeldung

Wählen Sie aus unserem Angebot Ihre Interessen aus!

Jetzt abonnieren
Jetzt abonnieren

Related Insights

Life Sciences & Gesundheitswesen

Biotech acquisition trend: radiopharmaceuticals

8. Mai 2024
Briefing

von Adrian Toutoungi

Klicken Sie hier für Details
Life Sciences & Gesundheitswesen

Early IP Strategy for Life Sciences Start-Ups Pays off

We explain the 5 biggest pitfalls

22. März 2024
Briefing

von Dr. Anja Lunze, LL.M. und Tobias Baus, LL.M., Dipl.-Ing.

Klicken Sie hier für Details
Medizinprodukte

Künstlich intelligente Medizinprodukte: Je besser das Produkt, desto schwieriger die Konformitätsbewertung?

27. Oktober 2023
Briefing

von Dr. Angela Knierim

Klicken Sie hier für Details